Urokinase-type plasminogen activator downregulates paraoxonase 1 expression in hepatocytes by stimulating peroxisome proliferator-activated receptor-γ nuclear export

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 2, 2012, Pages 449-458

  Khateeb, Jasmin ^a,b   Kiyan, Yulia ^c   Aviram, Michael ^a,b   Tkachuk, Sergey ^c   Dumler, Inna ^c   Fuhrman, Bianca ^a,b  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Hepatocytes; paraoxonase 1 (PON1); PPAR ; urokinase

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTERY WALL; ARTICLE; CONTROLLED STUDY; CYTOSOL; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME RELEASE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; LIPID PEROXIDATION; LIVER CELL; MALE; MOUSE; NONHUMAN; NUCLEAR EXPORT SIGNAL; OXIDATIVE STRESS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RAT; SIGNAL TRANSDUCTION; UPREGULATION;

ACTIVE TRANSPORT, CELL NUCLEUS; ANIMALS; ARYLDIALKYLPHOSPHATASE; CELL LINE, TUMOR; CELL NUCLEUS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; HEPATOCYTES; HUMANS; MALE; MAP KINASE KINASE KINASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MODELS, ANIMAL; OXIDATIVE STRESS; PPAR GAMMA; RATS; RATS, INBRED LEW; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; SIGNAL TRANSDUCTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84856228776     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.111.239889     Document Type: Article

References (43)

1. Stocker R, Keaney JF Jr New insights on oxidative stress in the artery wall. J Thromb Haemost. 2005;3:1825-1834.
2. Rozenberg O, Rosenblat M, Coleman R, Shih D, Aviram M. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Free Radic Biol Med. 2003;34: 774-784.
3. Mackness B, Hunt R, Durrington PN, and Mackness MI. Increased immunolocalization of paraoxonase, clusterin, and apolipoprotein A-I in the human artery wall with the progression of atherosclerosis. Arterioscler Thromb Vasc Biol. 1997;17:1233-1238.
4. Tavori H, Aviram M, Khatib S, Musa R, Nitecki S, Hoffman A, Vaya J. Human carotid atherosclerotic plaque increases oxidative state of macrophages and low-density lipoproteins, whereas paraoxonase 1 (PON1) decreases such atherogenic effects. Free Radic Biol Med. 2009;46:607-615.
5. Ikeda Y, Inoue M, Suehiro T, Arii K, Kumon Y, Hashimoto K. Low human paraoxonase predicts cardiovascular events in Japanese patients with type 2 diabetes. Acta Diabetol. 2009;46:239-242.
6. Shih DM, Lusis AJ. The roles of PON1 and PON2 in cardiovascular disease and innate immunity. Curr Opin Lipidol. 2009;20:288-292.
7. Deakin S, Leviev I, Gomaraschi M, Calabresi L, Franceschini G, James RW. Enzymatically active paraoxonase-1 is located at the external membrane of producing cells and released by a high affinity, saturable, desorption mechanism. J Biol Chem. 2002;277:4301-4308.
8. Waltz DA, Fujita RM, Yang X, Natkin L, Zhuo S, Gerard CJ, Rosenberg S, Chapman HA. Nonproteolytic role for the urokinase receptor in cellular migration in vivo. Am J Respir Cell Mol Biol. 2000;22:316-322.
9. Kienast J, Padro T, Steins M, Li CX, Schmid KW, Hammel D, Scheld HH, van de Loo JC. Relation of urokinase-type plasminogen activator expression to presence and severity of atherosclerotic lesions in human coronary arteries. Thromb Haemost. 1998;79:579-586.
10. Cozen AE, Moriwaki H, Kremen M, DeYoung MB, Dichek HL, Slezicki KI, Young SG, Veniant M, Dichek DA. Macrophage-targeted overexpression of urokinase causes accelerated atherosclerosis, coronary artery occlusions, and premature death. Circulation. 2004;109:2129-2135.
11. Fuhrman B, Nitzan O, Karry R, Volkova N, Dumler I, Aviram M. Urokinase plasminogen activator (uPA) stimulates cholesterol biosynthesis in macrophages through activation of SREBP-1 in a PI3-kinase and MEK-dependent manner. Atherosclerosis. 2007;195:e108-e116.
12. Gyongyosi M, Glogar D, Weidinger F, Domanovits H, Laggner A, Wojta J, Zorn G, Iordanova N, Huber K. Association between plasmin activation system and intravascular ultrasound signs of plaque instability in patients with unstable angina and non-st-segment elevation myocardial infarction. Am Heart J. 2004;147:158-164.
13. Menshikov M, Plekhanova O, Cai H, Chalupsky K, Parfyonova Y, Bashtrikov P, Tkachuk V, Berk BC. Urokinase plasminogen activator stimulates vascular smooth muscle cell proliferation via redox-dependent pathways. Arterioscler Thromb Vasc Biol. 2006;26:801-807.
14. Plekhanova OS, Men'shikov MY, Bashtrykov PP, Berk BC, Tkachuk VA, Parfenova EV. Urokinase induces ROS production in vascular smooth muscle cells. Bull Exp Biol Med. 2006;142:304-307.
15. Fuhrman B, Khateeb J, Shiner M, Nitzan O, Karry R, Volkova N, Aviram M. Urokinase plasminogen activator upregulates paraoxonase 2 expression in macrophages via an NADPH oxidase-dependent mechanism. Arterioscler Thromb Vasc Biol. 2008;28:1361-1367.
16. Fuhrman B, Gantman A, Khateeb J, Volkova N, Horke S, Kiyan J, Dumler I, AviramM. Urokinase activates macrophage PON2 gene transcription via thePI3K/ROS/MEK/SREBP-2 signalling cascade mediated by the PDGFR-β. Cardiovasc Res. 2009;84:145-154.
17. Kusch A, Tkachuk S, Haller H, Dietz R, Gulba DC, Lipp M, Dumler I. Urokinase stimulates human vascular smooth muscle cell migration via a phosphatidylinositol 3-kinase-Tyk2 interaction. J Biol Chem. 2000;275: 39466-39473.
18. Kiyan J, Kiyan R, Haller H, Dumler I. Urokinase-induced signaling in human vascular smooth muscle cells is mediated by PDGFR-β. EMBO J. 2005;24:1787-1797.
19. Blasi F, Sidenius N. The urokinase receptor:focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2010;584:1923-1930.
20. Aviram M, Rosenblat M. Paraoxonases (PON1, PON2, PON3) analyses in vitro and in vivo in relation to cardiovascular diseases. Methods Mol Biol. 2008;477:259-276.
21. Dahl JA, Collas P. A rapid micro chromatin immunoprecipitation assay (microChIP). Nat Protoc. 2008;3:1032-1045.
22. Aviram M, Vaya J. Markers for low-density lipoprotein oxidation. Methods Enzymol. 2001;335:244-256.
23. Schuerwegh AJ, Stevens WJ, Bridts CH, De Clerck LS. Evaluation of monensin and brefeldin A for flow cytometric determination of interleukin-1α , interleukin-6, and tumor necrosis factor-α in monocytes. Cytometry. 2001;46:172-176.
24. Nguyen SD, Sok DE. Oxidative inactivation of paraoxonase1, an antioxidant protein and its effect on antioxidant action. Free Radic Res. 2003;37:1319-1330.
25. Trudel K, Sinnett D, James RW, Delvin E, Amre D, Seidman E, Levy E. Iron-ascorbic acid-induced oxidant stress and its quenching by paraoxonase 1 in HDL and the liver: comparison between humans and rats. J Cell Biochem. 2005;96:404-411.
26. Khateeb J, Gantman A, Kreitenberg AJ, Aviram M, Fuhrman B. Paraoxonase 1 (PON1) expression in hepatocytes is upregulated by pomegranate polyphenols: a role for PPAR-α pathway. Atherosclerosis. 2010;208:119-125.
27. Yoon S, Seger R. The extracellular signal-regulated kinase: multiple substrates regulate diverse cellular functions. Growth Factors. 2006;24:21-44.
28. Burgermeister E, Chuderland D, Hanoch T, Meyer M, Liscovitch M, Seger R. Interaction with MEK causes nuclear export and downregulation of peroxisome proliferator-activated receptor γ . Mol Cell Biol. 2007;27: 803-817.
29. Durliat M, Komano O, Correc P, Burtin P. A receptor for plasminogen and plasmin on human and rat carcinoma cells. Evidence for strong interspecific reactivity. Thromb Res. 1991;64:637-645.
30. D'Alessio S, Blasi F. The urokinase receptor as an entertainer of signal transduction. Front Biosci. 2009;14:4575-4587.
31. Hu E, Kim JB, Sarraf P, Spiegelman BM. Inhibition of adipogenesis through MAP kinase-mediated phosphorylation of PPARδ . Science. 1996;274:2100-2103.
32. Kmieć Z. Cooperation of liver cells in health and disease. Adv Anat Embryol Cell Biol. 2001;161:III-XIII, 1-151.
33. Lee KH, Kim Jr Reactive oxygen species regulate the generation of urokinase plasminogen activator in human hepatoma cells via MAPK pathways after treatment with hepatocyte growth factor. Exp Mol Med. 2009;41:180-188.
34. Busso N, Nicodeme E, Chesne C, Guillouzo A, Belin D, Hyafil F. Urokinase and type I plasminogen activator inhibitor production by normal human hepatocytes: modulation by inflammatory agents. Hepatology. 1994;20:186-190.
35. Ng DS, Chu T, Esposito B, Hui P, Connelly PW, Gross PL. Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Cardiovasc Pathol. 2008;17:226-232.
36. Aviram M, Kaplan M, Rosenblat M, Fuhrman B. Dietary antioxidants and paraoxonases against LDL oxidation and atherosclerosis development. Handb Exp Pharmacol. 2005;170:263-300.
37. Aviram M, Rosenblat M, Bisgaier CL, Newton RS, Primo-Parmo SL, La Du BN. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions: a possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
38. Rozenberg O, Shih DM, Aviram M. Paraoxonase 1 (PON1) attenuates macrophage oxidative status: studies in PON1 transfected cells and in PON1 transgenic mice. Atherosclerosis. 2005;181:9-18.
39. M. Rosenblat, J. Vaya, D. Shih, and MAviram. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine, Atherosclerosis. 2005;179:69-77.
40. Fuhrman B, Gantman A, Aviram M. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Atherosclerosis. 2010;211:61-68.
41. Falkenberg M, Tom C, DeYoung MB, Wen S, Linnemann R, Dichek DA. Increased expression of urokinase during atherosclerotic lesion development causes arterial constriction and lumen loss, and accelerates lesion growth. Proc Natl Acad Sci USA. 2002;99:10665-10670.
42. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. [e-pub ahead of print Nov. 16]. Atherosclerosis. 2011.
43. Farris SD, Hu JH, Krishnan R, Emery I, Chu T, Du L, Kremen M, Dichek HL, Gold E, Ramsey SA, Dichek DA. Mechanisms of urokinase plasminogen activator (uPA)-mediated atherosclerosis: role of the uPA receptor and S100A8/A9 proteins. J Biol Chem. 2011;286:22665-22677.